Predicting arterial thrombosis in cancer patients
A Predictive Score for Arterial Thrombosis Associated With Cancer. The Prospective COMPASS- Arterial Cancer Associated Thrombosis Study
National and Kapodistrian University of Athens · NCT05256329
This study is trying to find out what factors can help predict the risk of blood clots in the arteries for cancer patients starting or undergoing treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | National and Kapodistrian University of Athens (other) |
| Locations | 1 site (Athens) |
| Trial ID | NCT05256329 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify clinical predictors of arterial thrombosis in ambulatory patients with specific types of cancer who are starting or have already begun anticancer treatment. It focuses on understanding the relationship between cancer and arterial thrombotic events, which have been less studied compared to venous thromboembolic events. By evaluating various risk factors, including cancer type and patient history, the study seeks to improve risk assessment models for arterial thrombosis in this population. The findings could lead to better management strategies for patients at risk of these complications.
Who should consider this trial
Good fit: Ideal candidates include ambulatory adults with histologically confirmed solid cancers or specific hematologic malignancies.
Not a fit: Patients under 18 years old, with a life expectancy of less than 3 months, or those with recent arterial thromboembolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict and prevent arterial thrombosis in cancer patients, potentially reducing morbidity and mortality.
How similar studies have performed: While the relationship between cancer and venous thromboembolic events has been extensively studied, the focus on arterial thrombosis in cancer patients is less established, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:Ambulatory cancer patients, with histologically confirmed solid cancer (breast, lung, gastric, colorectal, pancreatic, ovarian, prostate, or bladder cancer) or specific hematologic malignancy (Hodgkin and non-Hodgkin lymphoma or multiple myeloma) - Exclusion Criteria: a) age younger than 18 years, (b) life expectancy less than 3 months, (c) ongoing pregnancy, (d) recent (≤3 months) arterial thromboembolism and/or (e) major psychiatric disorder will be excluded from the study. -
Where this trial is running
Athens
- Konstantinos Toutouzas — Athens, Greece (RECRUITING)
Study contacts
- Study coordinator: Konstantinos KT Toutouzas, PhD
- Email: ktoutouz@gmail.com
- Phone: 6932289519
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer